Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 5:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–42 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Urothelial Cancer, Melanoma
Interventions
PF-07329640, sasanlimab, bevacizumab
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
4
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 1 more
Conditions
Microsatellite Stable (MSS) Colorectal Cancer (CRC), Metastatic Colorectal Cancer (CRC), Colorectal Cancer Stage IV
Interventions
Pre-Treatment Biopsy, On-Treatment Biopsy, Tiragolumab, Atezolizumab, Bevacizumab
Procedure · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Colorectal Cancer Metastatic
Interventions
isunakinra
Drug
Lead sponsor
Buzzard Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Newport Beach, California
Terminated Phase 1Phase 2 Interventional Results available

BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC

NCT03791398
Conditions
Metastatic Colorectal Cancer
Interventions
Dose level 1 ONC201 625mg, Dose level 2 ONC201 500mg, Dose level 3 ONC201 375mg
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Colorectal Cancer, Colorectal Cancer (CRC), Colorectal (Colon or Rectal) Cancer, CRC, Metastatic Colon Cancer, Colon Cancer, Advanced Colorectal Cancer
Interventions
CBI-1214
Biological
Lead sponsor
Cartography Biosciences
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 4 more
Conditions
Refractory Metastatic Colorectal Cancer
Interventions
TAS-102, nivolumab
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Denver, Colorado • Sarasota, Florida • Nashville, Tennessee
Conditions
Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Fluorouracil, Irinotecan, Ivonescimab, Leucovorin Calcium, Magnetic Resonance Imaging, Muzastotug
Procedure · Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Duarte, California
Conditions
Microsatellite Stable Metastatic Colorectal Cancer, Metastatic Colorectal Cancer, Colorectal Cancer
Interventions
Tiragolumab, Atezolizumab, Stereotactic Body Radiation Therapy (SBRT)
Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Refractory Metastatic Colorectal Cancer, pMMR, MSS
Interventions
RP2, RP3, atezolizumab, bevacizumab
Biological
Lead sponsor
Replimune, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Los Angeles, California • Seattle, Washington
Conditions
Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma
Interventions
PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo)
Drug · Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
8
States / cities
Beverly Hills, California • Fort Myers, Florida • Orlando, Florida + 4 more
Conditions
Metastatic Colorectal Cancer, Liver Metastases
Interventions
Dupilumab, Toripalimab
Drug
Lead sponsor
Dan Feng
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Conditions
Microsatellite Stable (MSS) Colorectal Adenocarcinomas, Colorectal Adenocarcinoma
Interventions
Nivolumab, Relatlimab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Refractory Colorectal Carcinoma, Stage IV Colorectal Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer, Stage IVC Colorectal Cancer, Colorectal Cancer Metastatic
Interventions
Metformin, Nivolumab
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia
Conditions
Metastatic Colorectal Cancer
Interventions
BNT314, Pumitamig, SoC chemotherapy treatment 1, SoC chemotherapy treatment 2, Bevacizumab
Biological · Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
4
States / cities
New Haven, Connecticut • Grand Rapids, Michigan • Cleveland, Ohio + 1 more
Conditions
Advanced Solid Tumors
Interventions
BMS-986484, Nivolumab, Oxaliplatin, Capecitabine, Fluorouracil, Calcium folinate
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Tucson, Arizona • Los Angeles, California • Grand Rapids, Michigan + 2 more
Conditions
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8
Interventions
Balstilimab, Bevacizumab, Biospecimen Collection, Botensilimab, Computed Tomography, Fluorouracil, Leucovorin Calcium, Magnetic Resonance Imaging, Oxaliplatin, Positron Emission Tomography, X-Ray Imaging
Biological · Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Duarte, California
Conditions
Colon Cancer
Interventions
Gevokizumab, Signatera test
Drug · Diagnostic Test
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
Gainesville, Florida • Iowa City, Iowa • New Brunswick, New Jersey + 2 more
Conditions
Colorectal Cancer
Interventions
Botensilimab, Balstilimab, Oxaliplatin, Leucovorin, Fluorouracil, Bevacizumab, Panitumumab
Drug
Lead sponsor
Nicholas DeVito, MD
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Durham, North Carolina